it looks like most buyouts recently have happened in late stage 2 of clinical trials - at least over the past year or so. So clearly we don't have to get to approval - but we need data late into a well powered trial.

before i did one of my paulson rounds (this was over a year ago), i remember Cyrus saying on a call to potential investors that the company would be launching a NASH trial (mentioned that the cost for a NASH Trial was much less than a cancer trial), and that the data readout would occur in 1.5 years or so from the beginning of the trial, and that would be our "inflection point" in terms of true value creation / as it would give the company the leverage to deal with a potential buyer.

so my assumption since then was that we get the hold lifted, attract a partner, start a trial funded by that partner, and wait for data to come in - and then sell for a lot of money. your post suggests that we already have the data that we would need to attract a buyer now? that would be great - and it's also possible that i misunderstood the call with Cyrus to some extent. but it leaves me wondering why we would even need to launch a trial if we already have the data we need to command a good price from a buyer.